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(77.55%) strains; and in 96.3% of subgenotype C (26/27) isolates.
Stop codon mutation on Pre-Core, G1896A, was found in 23 of 98
patients (23.47%); among them, 20 of 23 (86.96%) are genotype B.
Mutations related to antiviral drug resistance with frequency
more than 1% in the reverse transcriptase (RT) domain of
Polymerase gene were identified. 83.67% sequences have more
than one mutation. 50% sequences have mutation at rtI169V/M,
and all belong to sub-genotype B. Mutations at rtM204I/V and
rtM250I were present in 23.47% and 11.22% of isolates (23 and 11
of 98, respectively), and was higher in sub-genotype C (P-
values¼ 0.06 and<0.01, respectively). Our study provides high
precision whole genome sequences of the Vietnamese HBV pop-
ulation and shows potential information related to treatment
prediction for HBV infection as well as viral evolution. A further
study with larger sample size and intensive analysis combined
with clinical information promises more useful data for treat-
ment and invention.
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Since both HIV and HCV are known to be highly variable and
infections are treated with combination therapies that target
different viral proteins, random amplification followed by next-
generation sequencing could be an attractive alternative to
Sanger sequencing for obtaining complete viral genomes.
Moreover, one experimental approach could enable the simulta-
neous mapping of virus and human origin sequence reads,
which is of particular interest for the detection of single nucleo-
tide polymorphisms (SNPs) associated with disease progression
and treatment response. A plasma sample obtained from a
patient infected with HIV-1 recombinant subtype B and F1, and
diagnosed with AIDS; and another sample from an HCV infected
patient who progressed to fibrosis stage F1 were included in this
pilot study. They were both characterized by a high viral load,
i.e.>10M copies/ml for HIV and>3.5M IU/ml for HCV. Samples
were directly extracted or pre-treated with homogenisation,
centrifugation and filtration. Subsequently, purified nucleic
acids were subjected to targeted (HIV-1 PR-RT and HCV NS3 pro-
tease) amplification and Sanger sequencing, or to random
amplification followed by Illumina sequencing (2M paired end
reads attributed to each sample). Quality of the Illumina reads
was checked using FastQC, followed by a de novo assembly of
sample-specific contigs using the VICUNA and V-FAT software
packages. In total, 0.3% (n¼ 5557) and 0.02% (n¼ 421) of the
reads mapped to the HCV genome, respectively with or without
virus enrichment steps. This sufficed for the de novo generated
contigs to cover 98.3 and 51.3% of the HCV genome with and
without pre-treatment steps, respectively. Lower numbers of
reads could be mapped for HIV-1 (821 versus 196 without virus
enrichment), resulting in only 45.6 and 21.7% coverage of the
full-genome. For both samples, the number of reads (<2M) was
too low to map SNPs of interest within the human genome.
Subject to adaptations in the protocol, such as improved enrich-
ment strategies and deeper sequencing, this approach could be
suitable for the surveillance of local HIV-1 and HCV epidemics.
More extensive studies are required to investigate its usefulness
in clinical research.
A19 Genetic markers for protease inhibitor drug resistance in
regions outside of the protease gene
J. Giandhari,1,* M. Gordon,2 C. van Vuuren,3 P. Moodley,4
T. de Oliveira,1
1Africa Centre for Health and Population Studies, College of Health
Sciences, University of KwaZulu-Natal, 2HIV Pathogenesis
Programme, University of Kwa-Zulu Natal, Durban, South Africa,
3Military Hospital Division of Infectious Diseases, University of the
Free State, South Africa and 4Department of Virology, National
Health Laboratory Service, University of KwaZulu-Natal, Durban,
South Africa
There are currently 6.8 million individuals infected with HIV-1 in
South Africa. Nearly half of these individuals are on antiretroviral
therapy. Protease inhibitors (PIs) form part of the South African
national treatment guidelines as a first-line regimen for paediat-
ric patients and a second-line regimen for adults. However, suc-
cessful treatment is often hindered by the development of drug
resistance. Resistance to PIs is characterised by a stepwise accu-
mulation of mutations in the protease gene. However, studies
have shown a low frequency of mutations in patients failing PIs.
Regions outside of the protease, such as gag and more recently
env, have been associated with PI drug resistance in the absence
of protease mutations. We aim to identify genetic markers in the
gag and envelope genes which are associated with PI treatment
failure. Stored plasma samples from HIV-1-infected patients fail-
ing PI-based therapy (n ¼ 500) will be collected from collaborators
in South Africa and whole genome sequences from PI-naı¨ve
patients will be downloaded from the Los Alamos Sequence
Database. Failure will be defined as having two consecutive viral
loads>1,000 cpm after being on a PI-based regimen for6
months. The whole HIV-1 genome will be amplified from the PI
failures and sequenced using Illumina Miseq. Sequences will be
aligned to a reference and analysed for single nucleotide poly-
morphisms (SNPs) in all HIV genes using Geneious v 8.1.8 and
GATK software application. Genome wide association analysis
using PLINK will be performed to identify SNPs in PI treated
patients that are associated with treatment failure. Episodic
directional selection model such as MEDS and IFEL will be used to
identify mutations that occur at specific amino acid positions
and confer resistance to PIs. The previously mentioned methods
allow the identification of drug resistance mutations without the
need of baseline samples. Preliminary data from GWAS analysis
on 26 patients failing PI-based therapy has identified codons in
envelope and gag which are significantly associated with PI fail-
ure. Further examination of these sites in the viral minority popu-
lation has shown that they are present at>2% of the viral
population. By increasing our sample size we will obtain a more
comprehensive and robust analysis of the role of regions outside
the protease gene in PI resistance. Analysis of the control samples
is currently being performed.
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